Biblio Discovery — Demo Discovery Service

50 results for "Labaki, Chris"

Showing 1–20 · 0.67 seconds · RSS

  1. Journal Article Full text

    First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape

    Gulati, Shuchi; Labaki, Chris; Karachaliou, Georgia Sofia et al.

    Oncologist · 2022 · English · PubMed Central

    Treatment paradigm for metastatic clear cell renal cell carcinoma (mccRCC) has changed dramatically over the recent decades. From cytokines, interleukin-2 and interferon-α to tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors, during the last decade, combinations of immune…

  2. Journal Article Full text

    Differences in Kinematic Changes From Self-Selected to Fast Speed Gait in Asymptomatic Adults With Radiological Signs of Femoro-Acetabular Impingement

    Yared, Fares; Massaad, Abir; Bakouny, Ziad et al.

    Cureus · 2023 · English · PubMed Central

    Femoro-acetabular impingement (FAI) may present as alterations in the skeletal morphology of the hip. Repercussions of FAI can be witnessed in self-selected speed walking as well as physical exercise such as running or fast speed walking. The aim of this study was to investigate changes in…

  3. Journal Article Full text

    Perceptions of the COVID-19 vaccine among patients with cancer: a single-institution survey

    Moujaess, Elissar; Zeid, Naji Bou; Samaha, Ramy et al.

    Future Oncol · 2021 · English · PubMed Central

    Aims: This paper reports the results of a survey assessing the acceptance of the coronavirus disease 2019 (COVID-19) vaccine among patients with cancer. Patients and methods: In total, 111 adult patients with cancer from a single institution were asked to complete a questionnaire designed to assess…

  4. Journal Article Full text

    Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial

    Denize, Thomas; Farah, Subrina; Cimadamore, Alessia et al.

    Clin Cancer Res · 2022 · English · PubMed Central

    PURPOSE: Anti-angiogenic VEGF-receptor (VEGFR) inhibitors are approved for metastatic clear cell renal cell carcinoma (mccRCC) and their efficacy is higher in high angiogenic tumors. As cabozantinib inhibits multiple tyrosine kinase receptors, including VEGFRs, we tested whether markers of…

  5. Journal Article Full text

    Host immune signatures as predictors of response to immunotherapy-based regimens in patients with metastatic renal cell carcinoma (mRCC)

    Saad, Eddy; Labaki, Chris; Saliby, Renée-Maria et al.

    Oncologist · 2023 · English · PubMed Central

    BACKGROUND: Treatment options for mRCC have evolved to include VEGF targeted therapies (VEGF-TT), immune checkpoint inhibitors (ICIs), or combinations of both. However, clinical responses to systemic therapies in mRCC remain largely unpredictable and robust biomarkers are still lacking. The…

  6. Journal Article Full text

    Neutralizing antibody responses to the primary series of a COVID-19 mRNA vaccine in the cancer cohort under active treatment

    Xue, Huijing; Kemp, Troy J.; Li, Chenglei et al.

    Hum Vaccin Immunother · 2025 · English · PubMed Central

    Individuals with cancer are at increased risk of severe COVID-19 and immunogenicity of SARS-CoV-2 vaccines may be compromised, especially in those receiving systemic anti-cancer treatment. Understanding how treatment affects vaccine-induced humoral responses is critical to optimize vaccination…

  7. Journal Article Full text

    Integrative Analysis of Germline Rare Variants in Clear and Non-Clear Cell Renal Cell Carcinoma

    Han, Seunghun; Camp, Sabrina Y.; Chu, Hoyin et al.

    medRxiv · 2023 · English · PubMed Central

    IMPORTANCE: RCC encompasses a set of histologically distinct cancers with a high estimated genetic heritability, of which only a portion is currently explained. Previous rare germline variant studies in RCC have usually pooled clear and non-clear cell RCCs and have not adequately accounted for…

  8. Journal Article Full text

    24 Applying genomic analysis to refine unclassified renal cell carcinoma

    Yekeduz, Emre; Braun, David A; Chehade, Razane El Hajj et al.

    Oncologist · 2024 · English · PubMed Central

    BACKGROUND: Despite the improvements in genomic and pathological techniques to identify renal cell carcinoma (RCC), 2-6% of all patients with RCC cannot be classified into a particular subgroup, thus called “unclassified” RCC (uRCC). Ascertaining the genomic profile of those patients may help…

  9. Journal Article Full text

    Integrative Analysis of Germline Rare Variants in Clear and Non–clear Cell Renal Cell Carcinoma

    Han, Seung Hun; Camp, Sabrina Y.; Chu, Hoyin et al.

    Eur Urol Open Sci · 2024 · English · PubMed Central

    BACKGROUND AND OBJECTIVE: Previous germline studies on renal cell carcinoma (RCC) have usually pooled clear and non–clear cell RCCs and have not adequately accounted for population stratification, which might have led to an inaccurate estimation of genetic risk. Here, we aim to analyze the major…

  10. Journal Article Full text

    Implementing a context-augmented large language model to guide precision cancer medicine

    Jun, Hyeji; Tanaka, Yutaro; Johri, Shreya et al.

    medRxiv · 2025 · English · PubMed Central

    The rapid expansion of molecularly informed therapies in oncology, coupled with evolving regulatory FDA approvals, poses a challenge for oncologists seeking to integrate precision cancer medicine into patient care. Large Language Models (LLMs) have demonstrated potential for clinical applications…

  11. Journal Article Full text

    HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological study

    Naranbhai, Vivek; Viard, Mathias; Dean, Michael et al.

    Lancet Oncol · 2021 · English · PubMed Central

    BACKGROUND: Predictive biomarkers could allow more precise use of immune checkpoint inhibitors (ICI) in treating advanced cancers. Given the central role of HLA molecules in immunity, variation at the HLA loci may differentially impact response to ICI. The aim of this epidemiological study was to…

  12. Journal Article Full text

    Humoral immune responses to the second dose of a COVID-19 mRNA vaccine in cancer patients undergoing treatment

    Dang, Christine M.; Kemp, Troy J.; Roche, Nancy et al.

    Hum Vaccin Immunother · 2025 · English · PubMed Central

    The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak in 2020 led to the immediate development of vaccines to combat SARS-CoV-2 infections and coronavirus disease 2019 (COVID-19). First-generation (2020–2021) COVID-19 vaccines demonstrated high immunogenicity and efficacy…

  13. Journal Article Full text

    Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states

    Nyman, Jackson; Denize, Thomas; Bakouny, Ziad et al.

    bioRxiv · 2023 · English · PubMed Central

    Clear cell renal cell carcinoma (ccRCC) is molecularly heterogeneous, immune infiltrated, and selectively sensitive to immune checkpoint inhibition (ICI). Established histopathology paradigms like nuclear grade have baseline prognostic relevance for ccRCC, although whether existing or novel…

    Also available at: PubMed Central

  14. Journal Article Full text

    22 Association of a germline single nucleotide polymorphism (SNP) in the interleukin-7 (IL7) gene with immune-related adverse events (irAEs)

    Saad, Eddy; Mehrabad, Elnaz Mirazei; Labaki, Chris et al.

    Oncologist · 2024 · English · PubMed Central

    BACKGROUND: Adverse events (AEs) can limit treatment immune checkpoint inhibitors (ICI) efficacy and worsen patient outcomes. Our group recently identified a germline IL7 SNP as a potential biomarker for prediction of irAEs (Groha, Nat Med 2022). In the current study, we sought to replicate the…

  15. Journal Article Full text

    Characterization of the Cellular Origin and Oncogenic Mechanisms of Chromophobe Renal Cell Carcinoma (ChRCC) and Renal Oncocytic Neoplasms

    Labaki, Chris; Al-Choueiry, Michel; Nyman, Jackson et al.

    Oncologist · 2023 · English · PubMed Central

    BACKGROUND: ChRCC is a rare form of kidney cancer and presents with a poor prognosis in the metastatic setting, with limited response to immune checkpoint inhibitors (ICI) and targeted therapy. While previous studies suggested that ChRCC originates from intercalated cells of the kidney, its exact…

  16. Journal Article Full text

    Myeloid cells mediate interferon-driven resistance to immunotherapy in advanced renal cell carcinoma

    Bi, Kevin; Kashima, Soki; Camp, Sabrina Y. et al.

    Immunity · 2025 · English · PubMed Central

    Sustained type-I and type-II interferon (IFN) signaling can drive multiple mechanisms of resistance to immune checkpoint blockade (ICB). Here, we used single cell RNA-sequencing data to characterize the effects of IFNs in the tumor-immune microenvironment (TME) of renal cell carcinoma (RCC), then…

  17. Journal Article Full text

    14 Natural killer cells have impaired cytotoxicity in advanced renal cell carcinoma

    Moritz, Vivien; Xu, Wenxin; Birch, Grace et al.

    Oncologist · 2024 · English · PubMed Central

    BACKGROUND: Natural killer (NK) cells are key mediators of anti-tumor activity in multiple cancers, including clear cell renal cell carcinoma (ccRCC). However, the phenotype and function of NK cells across different disease stages of ccRCC is incompletely characterized. METHODS: Single-cell RNA…